You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

7 Items
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Adjuvant
Funding:
New Drug Funding Program
    Oxaliplatin - Adjuvant Colorectal Small Bowel or Appendiceal Cancer
Updated
Aug 2019
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Irinotecan - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Irinotecan - Second Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Bevacizumab (Biosimilar) - First Line - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Aug 2019
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Irinotecan - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for First Line Metastatic Colorectal Small Bowel or Appendiceal Cancer
Updated
Aug 2019
Cancer Type: Gastrointestinal, Pancreas     
Intent: Palliative
Funding:
New Drug Funding Program
    Oxaliplatin and Irinotecan - Advanced Pancreatic Cancer (FOLFIRINOX)
May 2017
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Adjuvant
Funding:
New Drug Funding Program
    Oxaliplatin - Adjuvant Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Oxaliplatin - With Surgery for Curative Intent for CRC SBAC Pts with Resectable or Potentially Resectable Liver Mets
Evidence Building Program
    Oxaliplatin (EBP) - Colorectal Cancer Patients with Resectable or Potentially Resectable Extrahepatic Metastases
Evidence Building Program
    Oxaliplatin (EBP) - Supplemental 1
Evidence Building Program
    Oxaliplatin (EBP) - Supplemental 2
Updated
Aug 2019
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Oxaliplatin - Second Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Oxaliplatin - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Bevacizumab (Biosimilar) - First Line - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Updated
Aug 2019
Cancer Type: Gastrointestinal, Colorectal, Small bowel and appendix     
Intent: Palliative
Funding:
New Drug Funding Program
    Oxaliplatin - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for First Line Metastatic Colorectal Small Bowel or Appendiceal Cancer
Updated
Aug 2019